指南与共识支持与姑息治疗

精准放疗联合分子靶向与免疫调节剂的ASTRO指南

Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.
指南 / 共识 · Lancet Oncol · 2018-01-01

该ASTRO指南基于精准放疗技术与基因组学个体化治疗的发展,探讨将放疗与分子靶向药物及免疫治疗联合以改善实体瘤生存的潜力,为联合治疗提供基础框架。

要点

  • 精准放疗应个体化基于基因表达谱反映的肿瘤与正常组织放射敏感性。
  • 联合分子靶向与免疫治疗是提高实体瘤生存的潜在方向。
  • 指南旨在为放疗联合分子靶向与免疫调节剂提供框架。

核心结论

  • 应严格探索放疗联合分子靶向药物与免疫治疗以改善癌症生存的潜在获益。

研究设计与样本

  • 美国放射肿瘤学会(ASTRO)制定的指南,基于精准放疗与精准肿瘤医学进展的主题基础。

主要发现

  • 精准放疗基于基因表达谱个体化处方放射剂量反映肿瘤与正常组织放射敏感性。
  • 精准肿瘤医学主要基于基因组学分析选择针对驱动突变、异常细胞信号、肿瘤微环境和遗传易感性的治疗。
  • 放疗技术安全提高局部肿瘤控制的能力增强,联合分子靶向与免疫治疗时机合适。

临床怎么用

  • 在精准放疗技术基础上,可考虑联合分子靶向药物与免疫治疗以改善实体瘤生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The practice of radiation oncology is primarily based on precise technical delivery of highly conformal, image-guided external beam radiotherapy or brachytherapy. However, systematic research efforts are being made to facilitate individualised radiation dose prescriptions on the basis of gene-expressssion profiles that reflect the radiosensitivity of tumour and normal tissue. This advance in precision radiotherapy should complement those benefits made in precision cancer medicine that use molecularly targeted agents and immunotherapies. The personalisation of cancer therapy, predicated largely on genomic interrogation, is facilitating the selection of therapies that are directed against driver mutations, aberrant cell signalling, tumour microenvironments, and genetic susceptibilities. With the increasing technical power of radiotherapy to safely increase local tumour control for many solid tumours, it is an opportune time to rigorously explore the potential benefits of combining radiotherapy with molecular targeted agents and immunotherapies to increase cancer survival outcomes. This theme provides the basis and foundation for this American Society for Radiation Oncology guideline on combining radiotherapy with molecular targeting and immunotherapy agents.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Bristow RG, Alexander B, Baumann M, et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncol. 2018. PMID: 29726389. doi:10.1016/S1470-2045(18)30096-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。